Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL6531474 | 0.98 | KDM4E (0.47) | KDM4EMYCSIGMAR1HDAC3HDAC1 | |
| SCHEMBL2281138 | 0.88 | HDAC6 (0.56) | KDM4ESIGMAR1HDAC3HDAC1HDAC10 | |
| Hydrochloric Acid SCHEMBL1026159 | 0.87 | HDAC6 (0.55) | KDM4ESIGMAR1HDAC3HDAC1HDAC10 | |
| SCHEMBL6531478 | 0.86 | KDM4E (0.44) | KDM4ESIGMAR1HDAC3HDAC1HDAC10 | |
| SCHEMBL2281130 | 0.83 | HDAC6 (0.60) | SIGMAR1HDAC3HDAC1HDAC10HDAC11 | |
| Hydrochloric Acid SCHEMBL1027994 | 0.82 | HDAC6 (0.59) | SIGMAR1HDAC3HDAC1HDAC10HDAC11 | |
| SCHEMBL1082426 | 0.78 | KDM4E (0.40) | KDM4ESIGMAR1SMN1; SMN2HDAC6KDM1A | |
| SCHEMBL3284599 | 0.78 | KMT2A (0.51) | KDM4EMYCHPGDKMT2AMEN1 | |
| SCHEMBL3284900 | 0.78 | ACE (0.42) | KDM4ESIGMAR1KDM1AALDH1A1 | |
| SCHEMBL1026202 | 0.77 | NOTUM (0.61) | MYCKMT2ASMN1; SMN2MEN1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | KDM4E 171/4885MYC 4493/4885SIGMAR1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.